Drs. Alberto Siller and Alberto Garcia are at it again at Clínica 0-19, peddling a dubious case series touting their DIPG treatment. Let’s just say that it does not demonstrate that their treatment is better than existing treatments; i.e., not very good.
Category: Clinical trials
Professor Fabrizio Benedetti is the most famous and almost certainly also the most influential researcher investigating the physiology of placebo effects. In a recent commentary, he asks whether placebo research is fueling quackery, as quacks co-opt its results. The answer to that question is certainly yes. A better question is: How do supporters of science counter the placebo narrative promoted by quacks, in which placebos represent the “power of the mind to heal the body”?
Studies done in mice often fail to translate to humans very well. A new study shows why, in neuroscience at least, mouse studies frequently don’t predict human results very well.
The ethics of pay-to-play clinical trials are a minefield. Last week the HHS Secretary’s Advisory Committee on Human Research Protections (SACHRP) stepped into that minefield. Are “pay-to-play” clinical trials ever ethically acceptable?
Stem cell therapies show great promise, but as yet the vast majority of that promise has not been validated in rigorous clinical trials. Unfortunately, for-profit stem cell clinics are running clinical trials that require patients to pay to be part of them (“pay-to-play”). These trials are not rigorous. Even more unfortunately, it appears that some universities are also running “pay-to-play” clinical trials that bear an uncomfortable resemblance to those run by for-profit clinics.